Brainstorm Cell Therapeutics (BCLI) Gets a Buy Rating from Maxim Group


In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI), with a price target of $9. The company’s shares closed yesterday at $3.95.

Palomeque noted:

“Brainstorm held a conference call to announce that the Health (MOH) approved its application to treat ALS patients with Pathway program. The news, in our view, is reflective of the urgent, unmet need in ALS. Thirteen ALS patients should now be able to receive NurOwn.”

According to TipRanks.com, Palomeque has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.9% and a 32.1% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, AzurRx BioPharma Inc, and Daré Bioscience Inc.

Currently, the analyst consensus on Brainstorm Cell Therapeutics is a Moderate Buy with an average price target of $10.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.35 and a one-year low of $2.92. Currently, Brainstorm Cell Therapeutics has an average volume of 72.01K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCLI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts